A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

Clinical trial NCT07264816 · RECRUITING

Trial details

NCT number: NCT07264816
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-squamous Non-small Cell Lung Cancer

Start date: 2026-02-03
Primary completion: 2027-12-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.